ArticleCureus2025
Assessment of Chromosomal Aberrations and S-phase Fraction in Patients With Esophageal Cancer.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- GenoTox Cell Counter: A mobile App to standardize cell counting in genotoxicity testing.Genetics and molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe varying pace of cell proliferation influences cancer development and persistent growth. S-phase fraction (SPF) refers to the percentage of cells in a tumor in the cell cycle phase, during which DNA is synthesized. SPF has been correlated with nuclear grade, tumor size, estrogen receptor, progesterone receptor, metastasis, and clinical response to neoadjuvant chemotherapy. Aberrations in the number and structure of chromosomes are a common feature of cells from solid tumors. The evaluation of the frequency of chromosomal aberrations in peripheral lymphocytes has been reported as a sensitive cytogenetic assay indicating cancer progression, especially in blood cancer. The present study assessed the correlation between chromosomal aberrations in peripheral blood lymphocytes (PBL) and SPF in the tumor tissue of esophageal cancer patients. MATERIALS AND
methodsThe present study included 172 subjects, 86 esophageal cancer patients and 86 unrelated age-gender-matched healthy controls. Cytogenetic analysis was done in 172 subjects after 72 hours of peripheral lymphocyte culturing and Giemsa-Trypsin Giemsa banding. SPF was performed in 86 tissue/biopsy samples of esophageal cancer patients using the in vitro bromodeoxyuridine technique.
resultsChromosomal aberrations were higher in esophageal cancer patients than in healthy controls. The mean (%) aberrant metaphases were significantly higher in patients (35.5 ± 13.3) than in controls (16.0 ± 6.6; p<0.0001). Similarly, mean (%) metaphases with structural aberrations were 16.3 ± 12.0 in patients versus 7.6 ± 5.0 in controls (p<0.0001), while mean (%) metaphases with numerical aberrations were 14.5 ± 7.4 in patients compared to 7.3 ± 4.3 in controls (p<0.0001), and mean (%) metaphases with both structural and numerical aberrations in patients were 4.8 ± 3.5 versus 1.1 ± 1.3 in controls (p<0.0001). Karyotype analysis revealed a higher frequency of chromosomal aberrations, including loss, gain, break, gap, deletion, addition, and translocations, affecting chromosomes 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, X, and Y in esophageal cancer patients. The mean SPF for stage I, stage II, stage III, and stage IV was 8.0±5.0, 8.2±4.8, 8.7 ± 4.2, and 10.8 ± 6.7, respectively. There was no significant difference in the mean SPF among different stages of esophageal cancer patients. However, it was in concordance with the pathological stage of the patients being lowest for the stage I patients and highest for the stage IV patients. The chromosomal aberrations in PBL were also lower in stage I (10%) and higher in stage IV (67%) patients.
conclusionsChromosomal aberrations obtained in lymphocytes of esophageal cancer patients showed highly significant differences from those of unrelated healthy controls. The SPF values were higher during the disease progression, with a corresponding high and increasing chromosomal instability in lymphocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.